TBPH
Theravance Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · KY
$17.08
+0.00%Year over year
Reported trailing growth
- Revenue
- +35.1%
- EBITDA
- +53.0%
- EBIT
- +112.5%
- EPS
- +325.5%
- Free cash flow
- -78.8%
- Operating cash flow
- -78.8%
Forward estimates
Based on analyst estimates
- Revenue
- -7.4%
- EBITDA
- +38.5%
- EPS
- +171.8%
Three-year CAGR
- Revenue
- +27.9%
- EBITDA
- +456.9%
- EBIT
- +71.8%
- Net income
- -50.5%
- EPS
- +282.6%
- Free cash flow
- +2109.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026